[-] Show simple item record

dc.contributor.authorGeurin, Michael D.eng
dc.contributor.authorSt. Anna, Leilanieng
dc.date.issued2010-12eng
dc.description.abstractThere is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting. (Strength of Recommendation: B, based on a single randomized controlled trial). Effects of TZD therapy on nonglycemic markers of metabolic syndrome are inconsistent compared with the effects of other hypoglycemic medications.eng
dc.identifier.citationAmerican Family Physician, 82(128) 2010: [1553]-1554.eng
dc.identifier.urihttp://hdl.handle.net/10355/11924eng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2010 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.subjectcardiac eventseng
dc.subjectpreventative measureseng
dc.subject.lcshCardiovascular emergencieseng
dc.titleThiazolidinedione Therapy for Managing Metabolic Syndromeeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record